Loading
Life sciences · Journal article
Frontiers in Microbiology · August 4, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing the current state of MRSA biology, resistance mechanisms, and emerging therapeutic approaches. It does not report original empirical data or comparative evidence but rather surveys the landscape of novel strategies (antimicrobial peptides, nanomedicine, bacteriophage therapy, CRISPR-Cas systems, monoclonal antibodies, plant-derived compounds) as potential alternatives or adjuncts to conventional antibiotics.
Narrative review. Patients with MRSA infections ranging from mild skin infections to severe invasive diseases including bacteremia, pneumonia, endocarditis, osteomyelitis, and sepsis.
MRSA resistance to β-lactams is conferred by the mecA gene encoding penicillin-binding protein 2a MRSA exhibits multidrug resistance through target-site mutations, efflux pumps, biofilm formation, horizontal gene transfer, and adaptive phenotypic variations Vancomycin-resistant Staphylococcus aureus has emerged, limiting conventional therapeutic options including vancomycin, linezolid, and daptomycin
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides clinicians and researchers with a comprehensive overview of MRSA pathogenesis and an organized survey of emerging therapeutic strategies. It contextualizes the urgent clinical need for novel approaches given the emergence of vancomycin-resistant strains.
This is a comprehensive narrative review synthesizing current knowledge on MRSA pathogenesis and emerging therapeutic strategies, providing expert perspective on the field rather than reporting original empirical evidence.
As stated by the source record.
This review provides clinicians and researchers with a comprehensive overview of MRSA pathogenesis and an organized survey of emerging therapeutic strategies. It contextualizes the urgent clinical need for novel approaches given the emergence of vancomycin-resistant strains.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most significant multidrug-resistant bacterial pathogens responsible for a broad spectrum of infections ranging from mild skin infections to severe invasive diseases, including bacteremia, pneumonia, endocarditis, osteomyelitis, and sepsis. The rapid global dissemination of MRSA is primarily driven by the acquisition of the mecA gene encoding penicillin-binding protein 2a, which confers resistance to β -lactam antibiotics. In addition to β-lactam resistance, MRSA exhibits resistance to multiple antimicrobial classes through diverse mechanisms, including target-site mutations, efflux pumps, biofilm formation, horizontal gene transfer, and adaptive phenotypic variations. The virulence and persistence of MRSA is further enhanced by numerous virulence factors such as adhesins, toxins, immune evasion proteins, and extracellular enzymes that facilitate colonization, persistence, and host tissue damage. Biofilm formation additionally contributes to chronic infection and antibiotic tolerance. Despite the availability of conventional agents such as vancomycin, linezolid, and daptomycin, the emergence of resistant strains including vancomycin-resistant Staphylococcus aureus has significantly limited current therapeutic options. Consequently, there is an urgent need for innovative therapeutic strategies. This review comprehensively summarizes the evolution, pathogenesis, virulence mechanisms, biofilm biology, and antibiotic resistance mechanisms of MRSA, with particular emphasis on emerging therapeutic approaches. Novel strategies including antimicrobial peptides, nanomedicine, bacteriophage therapy, CRISPR-Cas systems, biomimetic nano-NETs, probiotics, monoclonal antibodies and plant-derived compounds are discussed as promising alternatives or adjuncts to conventional antibiotics. Collectively, these advances highlight the evolving landscape of MRSA management and the potential for next-generation therapeutics to overcome antimicrobial resistance challenges.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.